Philip Morris
New Cetus Antibiotic
Fields
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Type
- REPT, OTHER REPORT
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Request
- Stmn/R1-004
- Stmn/R1-150
- Site
- R37
- Litigation
- Stmn/Produced
- Characteristic
- CONF, CONFIDENTIAL
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- hei84e00
Document Images
y--::~`~ ';` $':,-'
,Y~ _. _ .~,..
.. .-.J'+3F+i~.;a
- ' E.~~1 kl.;:
~ ~.4!

New Cetus Antibiotic
p
activity designed to discover new antibiotics. For the most part, this
Most major pharmaceutical companies presently carry out some form of
a number of totally different biological strategies to uncover new types
from soil samples, to find new antibiotic activity. Cetus has developed
4,
of antibiotic activity. We believe that each of our approaches is
l
high. 40 '( a ewr' s i -
q.;
the likelihood of having found a new and novel type ofvcompound is very
nature of our approach, should we find any antibiotic activity at all,
nove
, biologically sound and relatively easy to carry out. Due to the
a, . Q~- . 1 .,.j, ., ~L
examples of such protocols are outlined belowh
,` Z-ti~~ ,x
r :z~~ ''~as r `:t. ~W
, j...r.?
~
Biological Incorporation of Critical Precursor Mdlecules.?I'~'
possible that some of'the mutants will biochemically incorporate
broths of a large.'numbe"r of mutant microorganisms it is quite
compounds. one,addscdiaminobutyric acid to the fermentation
specifically
impart.th anti-gram negative activity to these
gram negative activity and'it is the diaminobutyric acid that seems ;,.
o
integral part of Gt~iese1`antibiotics. They both possess good anti
and colistin. Dzaminobutyricacid is an amino acid that forms an
Specific examples of~~this~phenomenon are the antibiotics polymixin~
and the "toxic segmen~ of the molecule" are separate and distinct.'.`;
limit their usefulness.Q~The "antibiotic segment of the molecule"
though these antibiotics have potent antimicrobial activity, they
also have serious shortcomings,-such as toxicity that seriously
part of several classes of antibiotics. Cenerally speaking, al-'.-
^
It is known that certain chemical moieties cons~itute an integral
useful antibiotics'with anti-gram negative activity. ..:;
aminobyturs.G, acid into totally new molecules yielding novel and
ChalLenging;Microorganisms with Hormones from Higher Animals.
~
"
b o
G,
g
animala`"such as mammals are chemicals totally foreign to microor-
Cetus~'investigators have shown that although hormones from hi
her
.ganisznsnonetheless they exert a profound effect on the internal,
chemisfry of the microorganism. It is possible that traditional
cortisone dramatically alters the way in which microorganisms .
metabolize amino acids and synthesize carotenoids. Since these
likely to be new and novel. For example, we have shown that hydro-,'
these new chemicals have antibiotic activity that activity is
ordinarily produced in their "natural metabolic state." If any of.,
of mammalian hormones would produce a large number of chemicals not
antibiotic-producing microorganisms fermenting under the influence
I activities are important in the production of known antibiotics,
might not the altered state produce totally new compounds?
, i ~ sc?..:y aa~ . r ~i. ~~r :.t, c:(c:i:tS+s , ; > u.i ~ ~:.`.'.`<x a?w K~..:~:.

`''_ f«"Ri'~ : SL. *.,N. ~. :.~ r >.e .s-, r ~, . ~',~~~~'' 1 ; . ,> f *i-: "7.
fui
it
'?:%
:°I. f:
GQ~
~.. .:::~' ....
, ~.~~.7 ~v .. l. ~,' ~{. _ .. ` _ ... .
~ . .-. ... .T', ~J. ...,... _...., ... ..
,l._.. . ~ .w ...A . ~~h:: _J.. _ ... l .,~...-i).f..
. .L ~J J. ~.r ~:.. ~ . ~,~'..S.l . ...... ...t Y. . .~
'~ . 3"'A~ °i :L3 _ . .. - ~,'11 ..:dr::i . _ .
~ , - .
-a.. . ~ -{:iy:~:a:S.-a'~ X .:f
.
. . .
... _ .y .__._
.. . .j'~c~j.'7::4~1 u~ .j~ '~.,.,. _. .;° -.
' ~ ~:x. ~ . . .. _ .. ~
.~.!_;y,;elE° -'
1T.~~'~r!'r'~+~
aA.
yr '.~'F`:

Mutating Microorganisms Known to be Non-Producers of Antibiotics.
,;.
:,:
Using Microorganisms to Modify Known Significant Antibioticy.s or
Their Precursors.
Many microorganisms are known that do not produce antibiotics of .
any type. Yet these organisms possess a complex internal chemistry
that, if altered by mutation, might conceivably produce antibiotic
activity. The Cetus technology would allow us to mutate large
numbers of such organisms, searching for evidence of any antibiotic
activity. The appealing aspect of this approach is that, because
of the expected low incidence of positives, very large numbers_of'.;
mutants can be screened quite easily. Here again, the potential
for novelty is high. `.-r' . _ i `.n .:r.,;.' c.. . ^Ci. - r. .., . .' r.~-fp"'Si''~t ,t',''r4 °
. .,'~ .~. a <~
precursors of compounds presently exhibiting-large m
arket share or
exciting potential. Microbiological moc~.ficationr& pharmaceutica
z
¢
l
Si
' 'r:. 'a,. r~ ~,.'~ ~IC Z
y
i l
~ ,`~ ~X'!. ~
K
..
,
Perhaps the most attractive proposal at Cetus,;kox generating new,;t~;r
antibiotics with a high likelihood of immediate~thera%utic and
market appeal involves biological modifica,~ionf'of com~ounds o
~
compounds produced elsewhere has,'~-avlrea&y~een expioited, e.g. in ~j_:,~
the steroid field. One specific examplef: We beiieve that our
approach has a high probabilify of success irrjaddressing situations
in which effectiveness andS~.abili~requirev~separate changes such as may be the case with Merck'
s:new; much-publicized thienamycin.
4`
~fi
O~ sSti~
- . `. -'i ,',_I
a o~~z °
G ti~, o~' o
04{ fi a~
fi
~~
~
, GO
~ti
.
G~
Qc` oofi
:K*h,14i
:z-
s`tj tr~
ra-s.,..r ~ .1
u.~.._.
z~` ~ A'r'~ ~ ~j c ~A~~~~"~}t l " f. ~. . ,~ . , ~ . . ' I ; ~ ' ~ n~ ., ';. t . ,
...tzi. . 1 <,t., '~: ;-fi.'~.`'~c3i11r...~ . s . . - .. .. . . , . ., . . . . . . . .. . . . . . .
_ . . , . . . -::k 1.- £~' _ .,s ..

---
